Results 21 to 30 of about 13,648 (298)

Mesalamine-Mediated Amelioration of Experimental Colitis in Piglets Involves Gut Microbiota Modulation and Intestinal Immune Cell Infiltration

Frontiers in Immunology, 2022
Mesalamine (MES), also known as 5-aminosalicylic acid, is effective in treating mild to moderate ulcerative colitis (UC). The mechanisms of its actions are not fully elucidated.
Yonggang Huang, Miaomiao Wu, Hao Xiao, Hongnan Liu, Guan Yang   +4 more
doaj   +2 more sources

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

Clinical and Experimental Gastroenterology, 2009
Glen A Doherty, Mark A PeppercornCenter for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA, USAAbstract: 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative ...
Glen A Doherty, Mark A Peppercorn
doaj   +3 more sources

Effects of Mesalamine Combined with Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules on Intestinal Mucosa Barrier Function and Intestinal Microbiota in Mildly Active Crohn’s Disease Patients

Journal of Investigative Surgery, 2023
Objective: This study is aimed at investigating the impact of mesalamine combined with Live combined Bifidobacterium, Lactobacillus and Enterococcus capsules on intestinal mucosa barrier function and intestinal microbiota in mildly active Crohn’s disease
Meiqin Shen, Yingqi Shi, Zhenming Ge, Junbo Qian   +3 more
doaj   +2 more sources

Drug-Induced Intersticial Nephritis. Clinical Case

Acta Medica Lituanica, 2021
5-Aminosalicylic acid (5-ASA) preparations are widely used in the treatment of inflammatory bowel diseases. The most commonly used medicine is mesalamine. Overall, it is a very safe drug with few side effects.
Paulina Tekoriutė, Monika Matuliauskaitė, Laimas Virginijus Jonaitis   +2 more
doaj   +1 more source

Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis. [PDF]

PLoS ONE, 2018
Mesalamine is commonly used to treat ulcerative colitis (UC). Although mesalamine acts topically, in vitro data suggest that intracellular transport is required for its beneficial effect.
Christopher J Moran, Hailiang Huang, Manuel Rivas, Jess L Kaplan, Mark J Daly, Harland S Winter   +5 more
doaj   +1 more source

Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review

Cureus, 2023
Ulcerative colitis (UC) management has changed significantly in the past decade. The goal is to treat the symptoms, aid tissue healing, and change the disease course to improve future outcomes.
Yurianna Santos, Arturo P Jaramillo
semanticscholar   +1 more source

Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study

Journal of Clinical Medicine, 2023
Background: Mesalamine is one of the most-used drugs in inflammatory bowel disease (IBD), especially ulcerative colitis. Regulatory agencies have listed mesalamine as an unsafe drug in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency ...
M. Dore, Giulia Tomassini, C. Rocchi, M. Bulajic, M. Carta, A. Errigo, Alberto Dimaggio, Federica Padedda, G. Pes   +8 more
semanticscholar   +1 more source

Recyclable mesalamine-functionalized magnetic nanoparticles (mesalamine/GPTMS@SiO2@Fe3O4) for tandem Knoevenagel–Michael cyclocondensation: grinding technique for the synthesis of biologically active 2-amino-4H-benzo[b]pyran derivatives

RSC Advances, 2023
In the present study, mesalamine-functionalized on magnetic nanoparticles (mesalamine/GPTMS@SiO2@Fe3O4) is fabricated as an efficient and magnetically recoverable nanocatalyst.
Mahdiyeh Partovi, Sobhan Rezayati, Ali Ramazani, Yavar Ahmadi, Hooman Taherkhani   +4 more
semanticscholar   +1 more source

Recurrent Pericarditis: A Rare Adverse Effect of Mesalamine

Cureus, 2023
Inflammation of the myocardium (myocarditis), pericardium (pericarditis), or both (myopericarditis) is a rare but potentially lethal side effect of mesalamine, a drug widely used in the treatment of inflammatory bowel disease (IBD).
Pratul Karki, Ariya Kunwar, N. Sharma, Megha Dogra   +3 more
semanticscholar   +1 more source

Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun? [PDF]

, 2009
5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine.
Lakatos, Péter László
core   +2 more sources